查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566771

Capecitabine市場：按適應症、藥物類型和最終用戶分類：2024-2033 年全球機會分析和產業預測

Capecitabine Market By Indication (Colorectal Cancer, Breast Cancer, Others) , By Drug Type (Branded, Generic) By End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球Capecitabine市場價值為4億美元，預計2024年至2033年複合年成長率為5%，到2033年將達7億美元。

Capecitabine是一種口服化療藥物，用於治療多種癌症，包括乳癌、結腸癌和直腸癌。Capecitabine屬於一組稱為抗代謝藥物的藥物，其作用是抑制癌細胞的生長和擴散。Capecitabine是前驅藥物，在體內轉化為其活性形式 5-Fluorouracil(5-FU)。一旦轉化，5-FU 就會抑制癌細胞中 DNA 和 RNA 的合成，導致癌細胞死亡。與靜脈注射的傳統化療不同，Capecitabine濱是口服的，通常是錠劑形式。這使得患者更加方便，並且通常可以在門診進行治療。

Capecitabine市場的成長是由癌症盛行率上升所推動的。隨著全球癌症患者數量的不斷增加，對有效治療方案的需求也迅速增加。此外，老年人口的增加已成為Capecitabine市場的關鍵促進因素。隨著年齡的成長，由於基因突變的累積、免疫系統減弱以及一生中長期接觸致癌物質等因素，我們變得更容易罹患癌症。人口老化的轉變導致老年人癌症診斷盛行率增加，從而對Capecitabine等有效癌症治療方法的需求增加。

然而，與Capecitabine相關的副作用，如貧血、胸部不適、嘔吐和凝血障礙，正在阻礙市場成長。同時，產品創新、推出和市場多元化為市場參與企業提供了有利的機會。例如，2022年12月，Shilpa Medicare Ltd.宣布推出Capecitabine1,000MG分散片，採用90秒內快速分散的新技術。該產品得到了必要的科學認證和比較生物等效性研究的支持，並得到了印度國家監管局（NRA）的批准，該機構負責確保印度醫療產品的安全性、有效性和質量，並獲得藥品標準控制組織的核准。該產品用於治療大腸直腸癌和轉移性乳癌。

分部概覽

全球Capecitabine市場按適應症、藥物類型、最終用戶和地區細分。依適應症分為大腸直腸癌、乳癌等。依藥品種類，藥品分為原廠藥和學名藥。依最終用戶分類，可分為醫院、居家醫療、專科中心等。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

有跡象表明，到 2023 年，乳癌細分市場將成為市場的最大股東。

按藥物類型分類，品牌細分市場在 2023 年佔據最高市場佔有率。

按最終用戶分類，2023 年醫院領域佔最大佔有率。

按地區分類，2023 年北美主導Capecitabine市場。

競爭場景

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章Capecitabine濱市場：依適應症分類

  • 市場概況
  • 大腸直腸癌
  • 乳癌
  • 其他

第5章Capecitabine濱市場：依藥物類型

  • 市場概況
  • 品牌
  • 非專利的

第6章Capecitabine市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 居家醫療
  • 專科診所
  • 其他

第7章Capecitabine濱市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國Capecitabine濱市場
    • 加拿大Capecitabine市場
    • 墨西哥Capecitabine市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國Capecitabine市場
    • 法國Capecitabine市場
    • 英國Capecitabine市場
    • 義大利Capecitabine市場
    • 西班牙Capecitabine市場
    • 其他歐洲Capecitabine市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本Capecitabine市場
    • 中國Capecitabine市場
    • 澳洲Capecitabine濱市場
    • 印度Capecitabine市場
    • 韓國Capecitabine市場
    • 其他亞太Capecitabine濱市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西卡培Capecitabine市場
    • 沙烏Capecitabine市場
    • 南非Capecitabine市場
    • 其他拉丁美洲/中東/非洲Capecitabine市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Novartis AG
  • Bayer AG
  • Eli Lilly And Company.
  • Merck And Co., Inc.
簡介目錄
Product Code: A03017

The global capecitabine market was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, leading to their death. Traditional chemotherapy drugs administered intravenously, whereas capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases.

The growth of the capecitabine market is driven by rise in the prevalence of cancer. With the growing number of cancer patients globally, there is surge in demand for the effective treatment option. Moreover, rise in geriatric population has emerged as a significant driver of the capecitabine market. As individuals age, they become more susceptible to developing cancer due to factors such as accumulated genetic mutations, weakened immune systems, and prolonged exposure to carcinogens over their lifetime. This demographic shift toward an aging population has led to a higher prevalence of cancer diagnoses among older adults, creating a greater demand for effective cancer treatments such as capecitabine.

However, adverse effects related to capecitabine, such as anemia, chest discomfort, vomiting, and blood clotting disorders, hamper the growth of the market. On the other hand, product innovation, launches, and diversification present lucrative opportunities for the market players. For instance, in December 2022, Shilpa Medicare Ltd. announced the launch of the Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds. The product is supported by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO) -the National Regulatory Authority (NRA) of India, responsible for ensuring the safety, efficacy, and quality of medical products in the country. The product is used for treatment of colorectal and metastatic breast cancer.

Segmentation Overview

The global capecitabine market is segmented into indication, drug type, end user, and region. By indication, the market is divided into colorectal cancer, breast cancer, and others. Depending on drug type, it is categorized into branded and generic. According to end user, the market is classified into hospitals, homecare, specialty centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By indication, the breast cancer segment was the largest shareholder in the market in 2023.

Depending on drug type, the branded segment held the highest market share in 2023.

According to end user, the hospitals segment accounted for the maximum share of the market in 2023.

Region wise, North America dominated the capecitabine market in 2023.

Competitive Scenario

The major players operating in the capecitabine market include F. Hoffmann-La Roche Ltd., Mylan N.V, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, and Merck & Co., Inc. Other players in the market include GlaxoSmithKline Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, and Alkem Labs Ltd. These players have adopted several strategies, including product diversification & innovation, mergers & acquisitions, and collaborations to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Indication

  • Colorectal Cancer
  • Breast Cancer
  • Others

By Drug Type

  • Branded
  • Generic

By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • F. Hoffmann-La Roche Ltd.
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Novartis AG
    • Bayer AG
    • Eli Lilly and Company.
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CAPECITABINE MARKET, BY INDICATION

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Indication
  • 4.2. Colorectal Cancer
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Breast Cancer
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Drug Type
  • 5.2. Branded
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Generic
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: CAPECITABINE MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Homecare
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Specialty Clinics
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CAPECITABINE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Indication
    • 7.2.3. Market Size and Forecast, By Drug Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Capecitabine Market
      • 7.2.6.1. Market Size and Forecast, By Indication
      • 7.2.6.2. Market Size and Forecast, By Drug Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Capecitabine Market
      • 7.2.7.1. Market Size and Forecast, By Indication
      • 7.2.7.2. Market Size and Forecast, By Drug Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Capecitabine Market
      • 7.2.8.1. Market Size and Forecast, By Indication
      • 7.2.8.2. Market Size and Forecast, By Drug Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Indication
    • 7.3.3. Market Size and Forecast, By Drug Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Capecitabine Market
      • 7.3.6.1. Market Size and Forecast, By Indication
      • 7.3.6.2. Market Size and Forecast, By Drug Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Capecitabine Market
      • 7.3.7.1. Market Size and Forecast, By Indication
      • 7.3.7.2. Market Size and Forecast, By Drug Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Capecitabine Market
      • 7.3.8.1. Market Size and Forecast, By Indication
      • 7.3.8.2. Market Size and Forecast, By Drug Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Capecitabine Market
      • 7.3.9.1. Market Size and Forecast, By Indication
      • 7.3.9.2. Market Size and Forecast, By Drug Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Capecitabine Market
      • 7.3.10.1. Market Size and Forecast, By Indication
      • 7.3.10.2. Market Size and Forecast, By Drug Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Capecitabine Market
      • 7.3.11.1. Market Size and Forecast, By Indication
      • 7.3.11.2. Market Size and Forecast, By Drug Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Indication
    • 7.4.3. Market Size and Forecast, By Drug Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Capecitabine Market
      • 7.4.6.1. Market Size and Forecast, By Indication
      • 7.4.6.2. Market Size and Forecast, By Drug Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Capecitabine Market
      • 7.4.7.1. Market Size and Forecast, By Indication
      • 7.4.7.2. Market Size and Forecast, By Drug Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Capecitabine Market
      • 7.4.8.1. Market Size and Forecast, By Indication
      • 7.4.8.2. Market Size and Forecast, By Drug Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Capecitabine Market
      • 7.4.9.1. Market Size and Forecast, By Indication
      • 7.4.9.2. Market Size and Forecast, By Drug Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Capecitabine Market
      • 7.4.10.1. Market Size and Forecast, By Indication
      • 7.4.10.2. Market Size and Forecast, By Drug Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Capecitabine Market
      • 7.4.11.1. Market Size and Forecast, By Indication
      • 7.4.11.2. Market Size and Forecast, By Drug Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Indication
    • 7.5.3. Market Size and Forecast, By Drug Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Capecitabine Market
      • 7.5.6.1. Market Size and Forecast, By Indication
      • 7.5.6.2. Market Size and Forecast, By Drug Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Capecitabine Market
      • 7.5.7.1. Market Size and Forecast, By Indication
      • 7.5.7.2. Market Size and Forecast, By Drug Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Capecitabine Market
      • 7.5.8.1. Market Size and Forecast, By Indication
      • 7.5.8.2. Market Size and Forecast, By Drug Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Capecitabine Market
      • 7.5.9.1. Market Size and Forecast, By Indication
      • 7.5.9.2. Market Size and Forecast, By Drug Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann-La Roche Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Mylan N.V.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Teva Pharmaceutical Industries Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Sanofi
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Pfizer Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Dr. Reddy's Laboratories Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Bayer AG
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Eli Lilly And Company.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Merck And Co., Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments